As flu cases surge, why don’t more people vaccinate?
Flu infections are rising sharply across the United States, contributing to at least 81,000 hospitalizations and 3,100 deaths so far this season, according to the U. S. Centers for… read more.
Flu infections are rising sharply across the United States, contributing to at least 81,000 hospitalizations and 3,100 deaths so far this season, according to the U. S. Centers for… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Dovprela. (pretomanid). The marketing… read more.
Researchers report that once-weekly treatment with islatravir plus lenacapavir (ISL+LEN) in virologically suppressed adults with HIV has safely maintained high rates of virologic suppression through 48 weeks. The… read more.
Multiple pre-exposure (PrEP) and postexposure (PEP) treatments are now available to prevent HIV infection. An updated Canadian guideline published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250511 contains 31 recommendations and 10 good practice… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Paxlovid (nirmatrelvir + ritonavir)…. read more.
NICE(UK): Cabotegravir is recommended as an option for pre-exposure prophylaxis (PrEP) alongside safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults and young… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for VacPertagen, a vaccine intended for prophylaxis against pertussis. The applicant… read more.
Shionogi & Co., Ltd. announced the launch of a new formulation of the anti-influenza virus drug Xofluza (baloxavir marboxil) – Xofluza Granules 2%. Until now, Xofluza has only… read more.
Roche announced that it has received CE mark for its Elecsys Dengue Ag test – a high-throughput, fully automated immunoassay to be used as an aid in the… read more.
Takeda announced the completion of the 7-year pivotal Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated])… read more.
Bavarian Nordic A/S announced the award of a joint procurement contract by the European Commission, through the Health Emergency Preparedness and Response Authority (HERA), enabling the EU, its… read more.
The electronic health record data analysed in this study is anonymised and never leaves a secure data environment, which is only accessible by approved researchers working on approved… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.